Botanix Director Granted Options Linked to Share Placement

Botanix Pharmaceuticals Limited ( (AU:BOT) ) has provided an announcement.

Botanix Pharmaceuticals has disclosed a change in the interests of director Vincent Ippolito, who holds both performance rights and fully paid ordinary shares, including interests via The Ippolito Trust. The notice reports that Ippolito has been granted 1,666,667 unquoted options exercisable at $0.06 and expiring on 31 January 2027, in connection with his participation in Tranche 2 of a share placement approved by shareholders.

The options were issued for nil cash consideration as a corresponding grant alongside the director’s placement subscription, and were approved at a general meeting held on 1 April 2026. The transaction occurred during a closed period but proceeded with prior written clearance and board and shareholder approval, underscoring the company’s adherence to ASX listing rules and corporate governance requirements on director dealings.

The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

More about Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Ltd is a biotechnology company focused on developing and commercialising pharmaceutical products. The company operates in the life sciences sector, with its shares listed on the ASX, and is governed by Australian corporate and securities regulations applicable to listed entities and their directors.

Average Trading Volume: 19,956,430

Technical Sentiment Signal: Sell

Current Market Cap: A$97.93M

Find detailed analytics on BOT stock on TipRanks’ Stock Analysis page.